Teva Pharmaceutical Industries Ltd. (TEVA) reported $3.89 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 1.9%. EPS of $0.52 for the same period compares to $0.48 a year ago.
The reported revenue represents a surprise of -1.92% over the Zacks Consensus Estimate of $3.97 billion. With the consensus EPS estimate being $0.47, the EPS surprise was +10.64%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- United States- Other: $109 million compared to the $110.05 million average estimate based on four analysts. The reported number represents a change of -18.1% year over year.
- Geographic Revenue- Europe- AJOVY: $58 million versus the four-analyst average estimate of $56.74 million. The reported number represents a year-over-year change of +13.7%.
- Geographic Revenue- International Markets- COPAXONE: $10 million versus $10.67 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -16.7% change.
- Geographic Revenue- International Markets- Generic products: $468 million versus the four-analyst average estimate of $487.47 million. The reported number represents a year-over-year change of -1.9%.
- Geographic Revenue- Europe- COPAXONE: $42 million compared to the $43.68 million average estimate based on four analysts. The reported number represents a change of -26.3% year over year.
- Geographic Revenue- Europe- Generic products: $989 million versus $991.61 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.5% change.
- Geographic Revenue- Europe- Other: $50 million versus the four-analyst average estimate of $95.70 million. The reported number represents a year-over-year change of -46.8%.
- Geographic Revenue- Europe- Respiratory products: $55 million compared to the $60.84 million average estimate based on four analysts. The reported number represents a change of -16.7% year over year.
- Geographic Revenue- International Markets- Other: $61 million versus $94.61 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -33% change.
- Geographic Revenue- United States: $1.91 billion compared to the $1.87 billion average estimate based on four analysts. The reported number represents a change of +10.7% year over year.
- Revenue- COPAXONE- Total: $106 million versus $84.97 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.1% change.
- Revenue- API sales to third parties: $130 million versus the two-analyst average estimate of $115.17 million. The reported number represents a year-over-year change of +1.6%.
Shares of Teva Pharmaceutical Industries have returned +18.6% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
